You might like
Let’s go
$DXB It seems that the market has forgotten all about #Dimerix So what can be expected in the next 4-8 weeks. FDA alignment on endpoints and for potential accelerated approval in FY26 The long awaited unblinding of the second interim analysis which needs to be statistically…
One would say if you believe in the success of LDX, then AT1 should also be considered. DYOR
$COV + 18% $LDX + 15% Holders of these stocks today are not too concerned about what the broader market is doing. $DXB still lagging but will have its time soon…
$COV 60c Now we have good volume…
$COV Up 7% on a day like today with reasonable volume for them. That’s Quality!!!
$COV 2026 to be the breakthrough year. CXCL10, Best in class test for #OvarianCancer with 95%sensitivity and 95% specificity.
🇦🇺 $COV Cleo adding to the US team gearing up for 2026. Big catalysts ahead. #asx #ASX200 #StockMarket #smallcap #Cleo #microcap #microcapgem
*STOCKS END HIGHER TO BOOK WEEKLY, MONTHLY GAINS AMID AI-FUELED RALLY
Oct 27, 2025 #Lithium Carbonate 99.5% Min China Spot Price: $10,739.64 1 day: $+161.34 (1.53%) 📈 YTD: +4.70% #Spodumene Concentrate (6%, CIF China) Price: $906.00 1 day: $+25.00 (2.84%) 📈 YTD: +11.03% Sponsored by @LibraLithium
$LDX 26.5c 🙏 We are so lucky in this community that there are some amazing people who can write up their thoughts so precise and eloquently…
Here are my views on $LDX $LDXHF: $LDX Positioned for a Major U.S. Re-Rating Event $LDX is nearing one of the most transformative milestones in its history, the FDA CLIA Waiver decision for its flagship test, FebriDx®. If approved, this breakthrough could expand Lumos’ market…
Good morning, the Australian share market looks set to climb on Monday following after a positive lead in from Wall Street on Friday. According to SPI futures, the ASX 200 index is expected to open 26 points or 0.3% higher this morning after ending last week with marginal gains.
Here are my views on $LDX $LDXHF: $LDX Positioned for a Major U.S. Re-Rating Event $LDX is nearing one of the most transformative milestones in its history, the FDA CLIA Waiver decision for its flagship test, FebriDx®. If approved, this breakthrough could expand Lumos’ market…
$LDX now 26c AGM today with MD Doug Ward confident #Febridx will be very successful and they won't have issues with moving the product. More importantly the US govt shutdown won't delay waiver approval which is expected from Nov-Feb.
$LDX AGM Concluded: No impact from FDA shutdown ✅ $317M based on 10% market penetration ✅ Low risk deal from LDX with PHASE ✅ No concern on Hologic takeover ✅ Cash flow positive ✅ More clinic signups expected ✅
$LDX The PRISM Trial (ISRCTN 15766538) is the first large real-world RCT of FebriDx in UK primary care. Interim data show reduced antibiotic use with no safety issues. If confirmed, FebriDx could become a validated global tool for better prescribing. #FebriDx #PRISMTrial #LDX
FebriDx by Lumos Diagnostics $LDX set to transform U.S. healthcare — market potential to grow 15× to over US$1B once FDA approved. Backed by BARDA, proven 99%+ accuracy, and prior FDA clearance, the odds of approval look strong. #ASX #LDX #Biotech #FDA #Investing
United States Trends
- 1. FINALLY DID IT 570 B posts
- 2. The Jupiter 342 B posts
- 3. Brigitte Bardot 175 B posts
- 4. Good Sunday 74,6 B posts
- 5. Tonges 1.783 posts
- 6. Namjoon 89,5 B posts
- 7. #sundayvibes 5.230 posts
- 8. Sunday of 2025 16,5 B posts
- 9. #AskFFT N/A
- 10. Cyclops 14,7 B posts
- 11. X-Men 35,4 B posts
- 12. Somali 537 B posts
- 13. Nick Shirley 307 B posts
- 14. Michael Carter N/A
- 15. Kittle 3.254 posts
- 16. Tim Walz 380 B posts
- 17. Taysom Hill N/A
- 18. Sunderland 30,4 B posts
- 19. Michael Wilson N/A
- 20. Kyle Williams 1.035 posts
Something went wrong.
Something went wrong.